ORKA
Oruka Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +7.1% ·
share flow +30.0% ·
net new positions +6.7%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 98 | +25 | 38.88M | $3.70B | +30 | −5 |
| Q1 2026 | 76 | +12 | 25.47M | $1.25B | +17 | −5 |
| Q4 2025 | 63 | +1 | 24.86M | $753.58M | +1 | n/a |
| Q3 2025 | 15 | +1 | 17.63M | $338.97M | +3 | −2 |
| Q2 2025 | 11 | 0 | 11.37M | $127.46M | +1 | −1 |
| Q1 2025 | 8 | +1 | 1.39M | $14.29M | +2 | −1 |
| Q4 2024 | 7 | +1 | 2.25M | $43.63M | +1 | n/a |
| Q3 2024 | 5 | +5 | 1.06M | $25.93M | +5 | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 7.26M | +29.2% | $139.56M | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 2 | Viking Global Investors ✦ | 2.67M | New | $51.28M | 0.1% | New | 1 | SEC ↗ |
| 3 | BlackRock ✦ (passive) | 2.20M | +10.8% | $42.39M | 0.0% | ▲ Add | 2 | SEC ↗ ×7 |
| 4 | The Vanguard Group ✦ (passive) | 1.78M | -2.2% | $34.17M | 0.0% | ▼ Trim | 2 | SEC ↗ ×3 |
| 5 | Point72 Asset Management ✦ | 1.04M | +214.2% | $19.94M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 689.97K | -2.5% | $13.27M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 7 | State Street Global Advisors ✦ (passive) | 652.03K | +74.9% | $12.54M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | T. Rowe Price ✦ | 626.81K | +52.5% | $12.05M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 9 | Citadel Advisors ✦ | 316.89K | New | $6.09M | 0.0% | New | 1 | SEC ↗ ×2 |
| 10 | Morgan Stanley ✦ | 134.83K | n/a | $2.59M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 11 | D. E. Shaw & Co. ✦ | 95.42K | +41.1% | $1.83M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Wellington Management ✦ | 91.09K | New | $1.75M | 0.0% | New | 1 | SEC ↗ ×3 |
| 13 | JPMorgan Chase ✦ | 28.96K | n/a | $556,862 | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 14 | Two Sigma Investments ✦ | 28.57K | -11.7% | $549,324 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 15 | Goldman Sachs Group ✦ | 19.77K | n/a | $380,273 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Viking Global Investors | $51.28M | 0.1% |
| Citadel Advisors | $6.09M | 0.0% |
| Wellington Management | $1.75M | 0.0% |
Exited
| Renaissance Technologies | $155,819 | was 0.0% |
| Millennium Management | $138,174 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 183 holders, 52.32M shares, $2.54B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 700 sh · $53,666
Officer · 1.40K sh · $105,677
Officer · 1.85K sh · $137,957
Officer · 2.85K sh · $210,806
Officer · 200 sh · $15,542
Officer · 200 sh · $16,567
Officer · 1.96K sh · $160,272
Officer · 2.10K sh · $169,596
Officer · 5.74K sh · $459,453
Officer · 2.67K sh · $254,196
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
19.5% of class · View original SEC filing ↗